A Phase 2 interventional study of ALKS 2680 and Placebo in Narcolepsy Type 2, sponsored by Alkermes, Inc.. Completed at 47 sites in 8 countries. Open to participants aged 18 Years to 70 Years. Per ClinicalTrials.gov, last updated 2026-02-27.
Sponsored by Alkermes, Inc. · Phase 2, Interventional, and Treatment
The purpose of this study is to measure the safety and decrease in sleepiness in subjects with narcolepsy type 2 (NT2) when taking ALKS 2680 tablets compared to placebo tablets.
157 studies on the registry are indexed under Narcolepsy; 37 are open to participants now.
This study's enrollment of 93 is above the median of 78 across 114 interventional studies indexed under Narcolepsy.
Browse Narcolepsy studies →Alkermes, Inc. is the lead sponsor of 83 studies on the registry; 9 are open to participants now.
Of its 9 completed or terminated interventional studies of FDA-regulated products, 5 (56%) have results posted.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Additionally, meets the following criteria:
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Oral tablet containing 10mg of ALKS 2680 for once daily administration
Drug: ALKS 2680
Oral tablet containing 14mg of ALKS 2680 for once daily administration
Drug: ALKS 2680
Oral tablet containing 18mg of ALKS 2680 for once daily administration
Drug: ALKS 2680
Oral tablet containing matching placebo for once daily administration
Drug: Placebo
Oral tablet containing ALKS 2680
Oral tablet containing placebo for once daily administration
Change in Mean Sleep Latency (MSL) on the Maintenance Wakefulness Test (MWT)
Time frame: Baseline to Week 8
Change in Epworth Sleepiness Scale (ESS)
Participants will be asked to complete the ESS, reporting on the level of sleepiness they experienced over the past 7 days.
Time frame: Baseline to week 8
Incidence of adverse events
Time frame: Up to 21 weeks
Plan to share: Undecided
This study is completed, as verified in Feb 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Alixorexton